In the latest trading session, 2.33 million Pacific Biosciences of California Inc (NASDAQ:PACB) shares changed hands as the company’s beta touched 2.02. With the company’s most recent per share price at $1.23 changing hands around $0.01 or 0.79% at last look, the market valuation stands at $336.74M. PACB’s current price is a discount, trading about -233.33% off its 52-week high of $4.10. The share price had its 52-week low at $1.16, which suggests the last value was 5.69% up since then. When we look at Pacific Biosciences of California Inc’s average trading volume, we note the 10-day average is 10.14 million shares, with the 3-month average coming to 11.24 million.
Analysts gave the Pacific Biosciences of California Inc (PACB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.19. If we narrow down to specifics, the data shows that 1 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended PACB as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Pacific Biosciences of California Inc’s EPS for the current quarter is expected to be -0.19.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Instantly PACB is in green as seen in intraday trades today. With action -11.54%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -32.81%, with the 5-day performance at -11.54% in the red. However, in the 30-day time frame, Pacific Biosciences of California Inc (NASDAQ:PACB) is -16.92% down. Looking at the short shares, we see there were 61.98 million shares sold at short interest cover period of 4.47 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 59.0% from its recent market value. According to analyst projections, PACB’s forecast low is 2 with 4 as the target high. To hit the forecast high, the stock’s price needs a -225.2% plunge from its current level, while the stock would need to soar -62.6% for it to hit the projected low.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Year-over-year growth is forecast to reach 5.07% up from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 33.66M. 12 analysts are of the opinion that Pacific Biosciences of California Inc’s revenue for the current quarter will be 38.09M. The company’s revenue for the corresponding quarters a year ago was 38.81M and 36.01M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -13.26%. The estimates for the next quarter sales put growth at 5.78%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.31%. The 2025 estimates are for Pacific Biosciences of California Inc earnings to increase by 33.82%, but the outlook for the next 5-year period is at 24.02% per year.
Pacific Biosciences of California Inc (NASDAQ:PACB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.29% of Pacific Biosciences of California Inc shares while 85.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 93.81%. There are 85.09% institutions holding the Pacific Biosciences of California Inc stock share, with ARK INVESTMENT MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 12.1932% of the shares, roughly 33.21 million PACB shares worth $45.5 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.6443% or 26.0 million shares worth $35.62 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. With 21.1 shares estimated at $25.54 million under it, the former controlled 7.71% of total outstanding shares. On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF held about 4.43% of the shares, roughly 12.12 shares worth around $14.67 million.
